Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$7.54
$0.09(1.22%)
At close: 4:00 PM EDT
$7.54
$0.09(1.22%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous Close$7.4
Volume576.45K
Average Volume (3M)1.28M
Market Cap
$630.98M
Enterprise Value$714.39
Total Cash (Recent Filing)$302.16M
Total Debt (Recent Filing)$404.11M
Price to Earnings (P/E)―
Beta3.05
Next Earnings
Nov 16, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding55,383,810
10 Day Avg. Volume1,560,604
30 Day Avg. Volume1,282,394
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside-7.16% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-3.5
Revenue Forecast (FY)$82.55M
Bulls Say, Bears Say
Bulls Say
Autonomous Lab ContractsContracts with leading universities and national research programs can deepen Ginkgo’s institutional relationships, validate its autonomous-lab platform, and create repeatable deployment experience. This supports longer-term credibility and may broaden adoption beyond individual customer R&D projects.
Low-Cost ADME OfferingADME-One’s substantial price advantage, alongside reported agreement with industry peers, gives Ginkgo a differentiated entry point in outsourced research services. If the offering scales, it could improve customer acquisition, utilization, and recurring demand for the broader platform.
Strong Gross MarginVery high gross margin indicates that delivered revenue has favorable direct economics, even though the company remains unprofitable overall. If Ginkgo can restore revenue growth and align operating expenses with its revenue base, this margin profile could support stronger incremental earnings.
Bears Say
Revenue ContractionThe sharp decline in quarterly and year-to-date revenue indicates that customer program activity and recognized commercial output are not yet providing a stable growth foundation. Continued contraction would reduce operating leverage, limit reinvestment capacity, and prolong the path toward sustainable profitability.
Persistent Losses And Cash BurnOngoing negative operating and free cash flow means Ginkgo still relies on its liquidity and financing capacity to fund operations. Large losses can constrain strategic investment and increase dependence on future cost reductions or capital raising before the platform becomes self-funding.
Rising LeverageThe substantial increase in leverage reduces financial flexibility while returns on equity remain deeply negative. Higher debt relative to shareholder capital can increase the burden on future cash generation and leave fewer options for funding platform investment or absorbing continued operating losses.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $630.98M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 51 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Aug 05, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.895 by $0.145.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Overvalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -1.01.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 55,383,810 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.895. Following the earnings report the stock price went down -9.285%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$7.00 (-7.16% Downside)
$7.00 (-7.16% Downside)
Blogger Sentiment
Neutral
DNA Sentiment 83%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 24.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 19.8%
Last 30 Days ▲ 19.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic and operational progress with near-term financial headwinds. Positives include major academic and national lab contracts, rapid expansion and scale demonstration of Nebula, a competitive ADME product with strong price/performance and a solid cash position plus a reduced long‑term Google Cloud commitment. Negatives include steep year‑over‑year revenue declines, wider GAAP losses and worse adjusted EBITDA in Q2, elevated quarter‑specific cash burn and ongoing excess lease costs. Management emphasizes cost discipline, a shift toward investing in autonomous labs and predictable cash burn guidance for 2026, but revenue recognition timing for automation deals and the need to further mature operations create near‑term uncertainty.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$7.00
▼(-7.16% Downside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
2.84% Insiders
15.30% Mutual Funds
25.78% Other Institutional Investors
40.49% Public Companies and
Individual Investors